Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (103408) 103408
Newsletter (14689) 14689
Book Review (13684) 13684
Publication (8560) 8560
Newspaper Article (4816) 4816
Book Chapter (854) 854
Conference Proceeding (789) 789
Dissertation (266) 266
Government Document (147) 147
Magazine Article (100) 100
Web Resource (72) 72
Trade Publication Article (54) 54
Reference (46) 46
Book / eBook (26) 26
Data Set (8) 8
Transcript (6) 6
Streaming Video (5) 5
Paper (4) 4
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (80260) 80260
humans (58733) 58733
epidermal growth factor (50163) 50163
animals (37235) 37235
female (25228) 25228
oncology (24332) 24332
cancer (21667) 21667
research (20354) 20354
male (18739) 18739
mice (16849) 16849
receptor, epidermal growth factor - metabolism (15343) 15343
cell biology (14406) 14406
biochemistry & molecular biology (14236) 14236
expression (12983) 12983
middle aged (11770) 11770
signal transduction (11418) 11418
mutation (11185) 11185
epidermal growth factor - pharmacology (11157) 11157
epidermal-growth-factor (10682) 10682
receptor, epidermal growth factor - genetics (10641) 10641
phosphorylation (10395) 10395
proteins (10373) 10373
aged (9766) 9766
adult (9750) 9750
analysis (9504) 9504
epidermal growth-factor (9422) 9422
cell line, tumor (9305) 9305
cells, cultured (9218) 9218
rats (9165) 9165
genetic aspects (8965) 8965
care and treatment (8919) 8919
tumors (8614) 8614
breast cancer (8226) 8226
receptor, epidermal growth factor - antagonists & inhibitors (8019) 8019
epidermal growth factor receptor (7870) 7870
gene expression (7820) 7820
chemotherapy (7743) 7743
kinases (7335) 7335
lung cancer (7329) 7329
immunohistochemistry (7322) 7322
metastasis (7168) 7168
egfr (7072) 7072
cell line (6981) 6981
epidermal growth factor receptors (6906) 6906
growth-factor receptor (6905) 6905
apoptosis (6891) 6891
cells (6822) 6822
epidermal growth factor - metabolism (6637) 6637
reports (6408) 6408
prognosis (6296) 6296
activation (6106) 6106
lung cancer, non-small cell (5764) 5764
tyrosine (5699) 5699
oncology, experimental (5696) 5696
health aspects (5684) 5684
gefitinib (5305) 5305
physiological aspects (5269) 5269
multidisciplinary sciences (5057) 5057
article (4991) 4991
antineoplastic agents - therapeutic use (4853) 4853
medicine (4816) 4816
research article (4797) 4797
cell proliferation (4791) 4791
molecular sequence data (4764) 4764
cancer therapies (4647) 4647
tumor cells, cultured (4557) 4557
aged, 80 and over (4454) 4454
pharmacology & pharmacy (4445) 4445
lung neoplasms - genetics (4443) 4443
lung neoplasms - drug therapy (4438) 4438
universities and colleges (4225) 4225
therapy (4198) 4198
abridged index medicus (4171) 4171
patients (4111) 4111
biochemistry (4034) 4034
medical research (4017) 4017
survival (4016) 4016
signal transduction - drug effects (4007) 4007
growth factors (3963) 3963
gene-expression (3961) 3961
development and progression (3942) 3942
proliferation (3891) 3891
amino acid sequence (3884) 3884
pathology (3869) 3869
antineoplastic agents - pharmacology (3842) 3842
protein (3838) 3838
genes (3836) 3836
factor receptor (3820) 3820
in-vitro (3818) 3818
growth (3772) 3772
rodents (3728) 3728
carcinoma (3670) 3670
cell division - drug effects (3667) 3667
differentiation (3666) 3666
carcinoma, non-small-cell lung - drug therapy (3659) 3659
receptor (3641) 3641
time factors (3616) 3616
lung neoplasms - pathology (3598) 3598
ligands (3581) 3581
surgery (3549) 3549
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (120429) 120429
Chinese (1304) 1304
Japanese (693) 693
French (496) 496
German (370) 370
Russian (314) 314
Spanish (221) 221
Korean (193) 193
Polish (89) 89
Hungarian (47) 47
Italian (43) 43
Portuguese (35) 35
Czech (31) 31
Turkish (29) 29
Dutch (12) 12
Bulgarian (11) 11
Danish (9) 9
Croatian (7) 7
Hebrew (7) 7
Ukrainian (7) 7
Persian (6) 6
Finnish (4) 4
Norwegian (4) 4
Romanian (4) 4
Swedish (4) 4
Lithuanian (3) 3
Serbian (2) 2
Slovak (2) 2
Catalan (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Epidermal growth factor
: methods and protocols
by Patel, Tarun B and Bertics, Paul J
2006, ISBN 1588294218, xi, 208
Electronic books | Epidermal growth factor | Laboratory manuals | Growth factors | local
Book
Details down arrow
2. Growth factors and development
by Nilsen-Hamilton, Marit
1990, ISBN 9780121531249, Volume 24., xv, 347
Facteurs de croissance
Book
Details down arrow
3. Full Text Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis
by Lee, June-Koo and Hahn, Seokyung and Kim, Dong-Wan and Suh, Koung Jin and Keam, Bhumsuk and Kim, Tae Min and Lee, Se-Hoon and Heo, Dae Seog
JAMA, ISSN 0098-7484, 04/2014, Volume 311, Issue 14, pp. 1430 - 1437
IMPORTANCE Current guidelines recommend both epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and cytotoxic chemotherapy drugs as... 
1ST-LINE ERLOTINIB | TRIAL | MEDICINE, GENERAL & INTERNAL | GEFITINIB | MULTICENTER | RANDOMIZED PHASE-3 | ADENOCARCINOMA | 2ND-LINE TREATMENT | OPEN-LABEL | MUTATIONS | EGFR | Disease-Free Survival | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Protein Kinase Inhibitors - therapeutic use | Humans | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Randomized Controlled Trials as Topic | Chemotherapy | Care and treatment | Research | Lung cancer, Non-small cell | Health aspects | Tyrosine metabolism | Cancer | Inhibitor drugs | Kinases | Lung cancer | Meta-analysis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
by Rosell, Rafael and Moran, Teresa and Queralt, Cristina and Porta, Rut and Cardenal, Felipe and Camps, Carlos and Majem, Margarita and Lopez-Vivanco, Guillermo and Isla, Dolores and Provencio, Mariano and Insa, Amelia and Massuti, Bartomeu and Gonzalez-Larriba, Jose Luis and Paz-Ares, Luis and Bover, Isabel and Garcia-Campelo, Rosario and Moreno, Miguel Angel and Catot, Silvia and Rolfo, Christian and Reguart, Noemi and Palmero, Ramon and Sánchez, José Miguel and Bastus, Roman and Mayo, Clara and Bertran-Alamillo, Jordi and Molina, Miguel Angel and Sanchez, Jose Javier and Taron, Miquel and Spanish Lung Canc Grp and Spanish Lung Cancer Group
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 958 - 967
Lung cancers with a mutation in the EGFR gene have heightened sensitivity to tyrosine kinase inhibitors. Asian patients have been the most intensively studied... 
GENE-MUTATIONS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | MUTANTS | SENSITIVE METHOD | ADENOCARCINOMAS | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | PROLONGED SURVIVAL | ACTIVATING MUTATIONS | ERLOTINIB | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Multivariate Analysis | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Young Adult | Exanthema - chemically induced | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Sex Distribution | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Care and treatment | Lung cancer | Diagnosis | Studies | Chemotherapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Tissue growth factors
by Abrahm, J and Baserga, Renato and Baserga, R
1981, ISBN 9783540106234, Volume 57., xxii, 630
Cell proliferation | Promoteurs | Growth | Tissus | Croissance | Tissues | Growth factors | Prolifération | Cellules
Book
Details down arrow
6. Full Text Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update
by Wolff, Antonio C and Hammond, M. Elizabeth H and Hicks, David G and Dowsett, Mitch and McShane, Lisa M and Allison, Kimberly H and Allred, Donald C and Bartlett, John M.S and Bilous, Michael and Fitzgibbons, Patrick and Hanna, Wedad and Jenkins, Robert B and Mangu, Pamela B and Paik, Soonmyung and Perez, Edith A and Press, Michael F and Spears, Patricia A and Vance, Gail H and Viale, Giuseppe and Hayes, Daniel F and American Society of Clinical Oncology and College of American Pathologists
Archives of Pathology and Laboratory Medicine, ISSN 0003-9985, 02/2014, Volume 138, Issue 2, pp. 241 - 256
Purpose. To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth... 
MEDICINE, RESEARCH & EXPERIMENTAL | TISSUE MICROARRAY TECHNOLOGY | ADJUVANT TRASTUZUMAB BENEFIT | IN-SITU HYBRIDIZATION | TIME RT-PCR | PATHOLOGY | CORE NEEDLE-BIOPSY | ESTROGEN-RECEPTOR | ASCO/CAP HER2-POSITIVITY CRITERIA | HER2 GENE AMPLIFICATION | RABBIT MONOCLONAL-ANTIBODY | POLYMERASE CHAIN-REACTION | MEDICAL LABORATORY TECHNOLOGY | Immunohistochemistry | Predictive Value of Tests | Neoplasm Invasiveness | United States | Humans | Receptor, ErbB-2 - metabolism | In Situ Hybridization, Fluorescence | Mammary Glands, Human - pathology | Mammary Glands, Human - metabolism | Neoplasm Proteins - metabolism | Breast Neoplasms - metabolism | Societies, Medical | Breast Neoplasms - pathology | Biomarkers, Tumor - metabolism | Female | Breast Neoplasms - diagnosis | Relapse | Epidermal growth factor | Medical societies | Practice guidelines (Medicine) | Breast cancer | Evidence-based medicine | Diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
by Yano, Seiji and Wang, Wei and Li, Qi and Matsumoto, Kunio and Sakurama, Haruko and Nakamura, Takahiro and Ogino, Hirokazu and Kakiuchi, Soji and Hanibuchi, Masaki and Nishioka, Yasuhiko and Uehara, Hisanori and Mitsudomi, Tetsuya and Yatabe, Yasushi and Nakamura, Toshikazu and Sone, Saburo
Cancer Research, ISSN 0008-5472, 11/2008, Volume 68, Issue 22, pp. 9479 - 9487
Lung cancer with epidermal growth factor receptor (EGFR)activating mutations responds favorably to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib.... 
AMPLIFICATION | GENE | ONCOLOGY | TYROSINE KINASE | C-MET | ACQUIRED-RESISTANCE | PHASE-II | GASTROINTESTINAL STROMAL TUMORS | EGFR | CANCER CELL-LINES | FACTOR-ALPHA | Proto-Oncogene Proteins - metabolism | Lung Neoplasms - drug therapy | Phosphorylation | Receptor, ErbB-3 - metabolism | Humans | Proto-Oncogene Proteins c-met | Drug Resistance, Neoplasm | Proto-Oncogene Proteins - genetics | Hepatocyte Growth Factor - pharmacology | Adenocarcinoma - drug therapy | Receptors, Growth Factor - genetics | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mutation | Proto-Oncogene Proteins c-akt - metabolism | Quinazolines - pharmacology | Receptor, Epidermal Growth Factor - physiology | Receptors, Growth Factor - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
by Hata, Aaron N and Niederst, Matthew J and Archibald, Hannah L and Gomez-Caraballo, Maria and Siddiqui, Faria M and Mulvey, Hillary E and Maruvka, Yosef E and Ji, Fei and Bhang, Hyo-Eun C and Radhakrishna, Viveksagar Krishnamurthy and Siravegna, Giulia and Hu, Haichuan and Raoof, Sana and Lockerman, Elizabeth and Kalsy, Anuj and Lee, Dana and Keating, Celina L and Ruddy, David A and Damon, Leah J and Crystal, Adam S and Costa, Carlotta and Piotrowska, Zofia and Bardelli, Alberto and Iafrate, Anthony J and Sadreyev, Ruslan I and Stegmeier, Frank and Getz, Gad and Sequist, Lecia V and Faber, Anthony C and Engelman, Jeffrey A
Nature Medicine, ISSN 1078-8956, 03/2016, Volume 22, Issue 3, pp. 262 - 269
Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non -small -cell lung cancers to EGFR inhibitors have been... 
EGFR KINASE INHIBITORS | MEDICINE, RESEARCH & EXPERIMENTAL | GEFITINIB | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | T790M | CELL BIOLOGY | HETEROGENEITY | LUNG-CANCER | MET AMPLIFICATION | MODELS | MUTATION | AZD9291 | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Apoptosis - genetics | RNA, Messenger - metabolism | Gene Expression Regulation, Neoplastic - drug effects | RNA, Messenger - drug effects | Lung Neoplasms - genetics | Cell Survival - drug effects | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Drug Resistance, Neoplasm - genetics | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Cell Cycle - drug effects | In Vitro Techniques | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Development and progression | Genetic aspects | Research | Drug resistance | Drug therapy | Risk factors | Tumors | Epidermal growth factor | Inhibitor drugs | Neurons | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Intranasal epidermal growth factor treatment rescues neonatal brain injury
by Scafidi, Joseph and Hammond, Timothy R and Scafidi, Susanna and Ritter, Jonathan and Jablonska, Beata and Roncal, Maria and Szigeti-Buck, Klara and Coman, Daniel and Huang, Yuegao and McCarter Jr, Robert J and Hyder, Fahmeed and Horvath, Tamas L and Gallo, Vittorio
Nature, ISSN 0028-0836, 2014, Volume 506, Issue 7487, pp. 230 - 234
There are no clinically relevant treatments available that improve function in the growing population of very preterm infants (less than 32 weeks' gestation)... 
MULTIPLE-SCLEROSIS | LOW-BIRTH-WEIGHT | OLIGODENDROCYTE PROGENITORS | MULTIDISCIPLINARY SCIENCES | HYPOXIC INJURY | CENTRAL-NERVOUS-SYSTEM | MOUSE CORPUS-CALLOSUM | PRETERM INFANTS | RAT-BRAIN | WHITE-MATTER ABNORMALITIES | FACTOR RECEPTOR | Epidermal Growth Factor - administration & dosage | Oligodendroglia - metabolism | Receptor, Epidermal Growth Factor - genetics | Demyelinating Diseases - congenital | Brain Injuries - drug therapy | Humans | Brain Injuries - congenital | Male | Stem Cells - cytology | Demyelinating Diseases - metabolism | Epidermal Growth Factor - therapeutic use | Molecular Targeted Therapy | Stem Cells - metabolism | Cell Lineage - drug effects | Hypoxia - metabolism | Receptor, Epidermal Growth Factor - metabolism | Oligodendroglia - drug effects | Time Factors | Oligodendroglia - cytology | Demyelinating Diseases - pathology | Disease Models, Animal | Animals, Newborn | Cell Survival - drug effects | Demyelinating Diseases - prevention & control | Administration, Intranasal | Infant, Premature, Diseases - drug therapy | Cell Division - drug effects | Brain Injuries - prevention & control | Oligodendroglia - pathology | Hypoxia - genetics | Regeneration - drug effects | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Hypoxia - pathology | Stem Cells - drug effects | Hypoxia - physiopathology | Infant, Premature, Diseases - metabolism | Mice | Epidermal Growth Factor - pharmacology | Brain Injuries - pathology | Infant, Premature, Diseases - pathology | Brain | Medical research | Care and treatment | Infants (Premature) | Risk factors | Complications and side effects | Epidermal growth factor | Physiological aspects | Medicine, Experimental | Hypoxia | Diagnosis | Health aspects | Injuries | Attention deficit disorder | Brain damage | Rodents | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
by Wilson, Timothy R and Fridlyand, Jane and Yan, Yibing and Penuel, Elicia and Burton, Luciana and Chan, Emily and Peng, Jing and Lin, Eva and Wang, Yulei and Sosman, Jeff and Ribas, Antoni and Li, Jiang and Moffat, John and Sutherlin, Daniel P and Koeppen, Hartmut and Merchant, Mark and Neve, Richard and Settleman, Jeff
Nature, ISSN 0028-0836, 07/2012, Volume 487, Issue 7408, pp. 505 - 509
Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy(1). However, the efficacy of kinase inhibitors in... 
CELL LUNG-CANCER | SURVIVAL | HETEROGENEITY | ACTIVATION | RECEPTOR TYROSINE KINASES | THERAPY | MET AMPLIFICATION | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | SENSITIVITY | TUMOR-CELLS | Receptor, ErbB-2 - genetics | Humans | Receptor, ErbB-2 - metabolism | Melanoma - enzymology | Phosphatidylinositol 3-Kinases - metabolism | Hepatocyte Growth Factor - pharmacology | Breast Neoplasms - metabolism | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Breast Neoplasms - drug therapy | Hepatocyte Growth Factor - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Ligands | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Mitogen-Activated Protein Kinases - metabolism | Antimitotic agents | Physiological aspects | Antineoplastic agents | Growth factors | Health aspects | Phosphotransferases | Substance abuse treatment | Epidermal growth factor | Rodents | Biomarkers | Breast cancer | Insulin-like growth factors | Kinases | Drug resistance | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
by Kris, Mark G and Natale, Ronald B and Herbst, Roy S and Lynch, Jr, Thomas J and Prager, Diane and Belani, Chandra P and Schiller, Joan H and Kelly, Karen and Spiridonidis, Harris and Sandler, Alan and Albain, Kathy S and Cella, David and Wolf, Michael K and Averbuch, Steven D and Ochs, Judith J and Kay, Andrea C
JAMA, ISSN 0098-7484, 10/2003, Volume 290, Issue 16, pp. 2149 - 2158
CONTEXT More persons in the United States die from non–small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In... 
MEDICINE, GENERAL & INTERNAL | ZD1839 IRESSA(TM) | THERAPY | CHEMOTHERAPY REGIMENS | FUNCTIONAL ASSESSMENT | PLATINUM | EXPRESSION | DOCETAXEL | TUMORS | IMATINIB MESYLATE | EGFR | Lung Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Lung Neoplasms - physiopathology | Carcinoma, Non-Small-Cell Lung - physiopathology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Enzyme Inhibitors - adverse effects | Double-Blind Method | Administration, Oral | Treatment Outcome | Enzyme Inhibitors - therapeutic use | Radiography | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Lung Neoplasms - diagnostic imaging | Aged | Carcinoma, Non-Small-Cell Lung - diagnostic imaging | Carcinoma, Non-Small-Cell Lung - drug therapy | Pharmaceutical industry | Lung cancer, Non-small cell | Drug therapy | Product information | Clinical trials | Disease management | Lung cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The genomic landscape of response to EGFR blockade in colorectal cancer
by Bertotti, Andrea and Papp, Eniko and Jones, Siân and Adleff, Vilmos and Anagnostou, Valsamo and Lupo, Barbara and Sausen, Mark and Phallen, Jillian and Hruban, Carolyn A and Tokheim, Collin and Niknafs, Noushin and Nesselbush, Monica and Lytle, Karli and Sassi, Francesco and Cottino, Francesca and Migliardi, Giorgia and Zanella, Eugenia R and Ribero, Dario and Russolillo, Nadia and Mellano, Alfredo and Muratore, Andrea and Paraluppi, Gianluca and Salizzoni, Mauro and Marsoni, Silvia and Kragh, Michael and Lantto, Johan and Cassingena, Andrea and Li, Qing Kay and Karchin, Rachel and Scharpf, Robert and Sartore-Bianchi, Andrea and Siena, Salvatore and Diaz, Luis A and Trusolino, Livio and Velculescu, Victor E
Nature, ISSN 0028-0836, 10/2015, Volume 526, Issue 7572, pp. 263 - 267
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly... 
PANITUMUMAB | THERAPY | MULTIDISCIPLINARY SCIENCES | SEQUENCE | ACQUIRED-RESISTANCE | SOMATIC MUTATION | IDENTIFICATION | GENE COPY NUMBER | ACTIVATING MUTATIONS | BREAST | INSIGHTS | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Genomics | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Molecular Targeted Therapy | Receptor, Fibroblast Growth Factor, Type 1 - genetics | MAP Kinase Kinase 1 - genetics | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Insulin Receptor Substrate Proteins - genetics | Colorectal Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Cetuximab - pharmacology | DNA Copy Number Variations - genetics | Mutation - genetics | Genome, Human - genetics | Receptor, Epidermal Growth Factor - chemistry | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Exome - genetics | Animals | Receptor, Platelet-Derived Growth Factor alpha - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Gene mutations | Colorectal cancer | Drug metabolism | Genetic aspects | Identification and classification | Health aspects | Proteins | Epidermal growth factor | Genes | Clinical trials | Mutation | Kinases | Cancer therapies | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights